Skip to main content

Pliant Therapeutics, Inc. (PLRX)

NASDAQ: PLRX · IEX Real-Time Price · USD
17.28 -0.38 (-2.15%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap621.01M
Revenue (ttm)13.24M
Net Income (ttm)-81.25M
Shares Out35.75M
EPS (ttm)-2.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume47,277
Open17.70
Previous Close17.66
Day's Range17.10 - 18.07
52-Week Range16.08 - 43.92
Betan/a
AnalystsBuy
Price Target51.33 (+197.0%)
Est. Earnings DateNov 9, 2021

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also deve...

IndustryBiotechnology
IPO DateJun 3, 2020
CEOBernard Coulie
Employees90
Stock ExchangeNASDAQ
Ticker SymbolPLRX
Full Company Profile

Financial Performance

In 2020, PLRX's revenue was $41.82 million, a decrease of -26.70% compared to the previous year's $57.05 million. Losses were -$41.53 million, 6,482.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PLRX stock is "Buy." The 12-month stock price forecast is 51.33, which is an increase of 197.05% from the latest price.

Price Target
$51.33
(197.05% upside)
Analyst Consensus: Buy

News

Pliant Therapeutics to Participate in Piper Sandler Lung Day

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics f...

2 weeks ago - GlobeNewsWire

Why Pliant Therapeutics Stock Is Surging Today

A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.

1 month ago - The Motley Fool

Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 i...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

1 month ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021

5 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics fo...

5 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

6 months ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021

7 months ago - GlobeNewsWire

Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Ph...

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies...

7 months ago - GlobeNewsWire

Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies ...

9 months ago - GlobeNewsWire

Pliant Therapeutics: An Early Stage Company With Important Collaborations

PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.

10 months ago - Seeking Alpha

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel ther...

11 months ago - PRNewsWire

Pliant Therapeutics to Present Data at The Liver Meeting® 2020

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...

11 months ago - PRNewsWire

Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

1 year ago - PRNewsWire

Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

1 year ago - PRNewsWire

Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

1 year ago - PRNewsWire

Could This Recent IPO Biotech Become the Next Moderna?

There's a chance that it could become an even bigger success story.

1 year ago - The Motley Fool

Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional S...

SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for t...

1 year ago - PRNewsWire

Pliant Therapeutics Shares Have Climbed 44% Since This Week’s IPO

Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.

1 year ago - GuruFocus

Pliant Therapeutics Up 33% on IPO Pricing

Investors are excited about the biotech's prospects, but the company still has a long road ahead.

1 year ago - The Motley Fool

Pliant Therapeutics shares soar 55% in trading debut

Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.

1 year ago - Market Watch